216 related articles for article (PubMed ID: 36435510)
1. Prognostic value and immunological role of FOXM1 in human solid tumors.
Wei G; Yang X; Lu H; Zhang L; Wei Y; Li H; Zhu M; Zhou X
Aging (Albany NY); 2022 Nov; 14(22):9128-9148. PubMed ID: 36435510
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and Immunological Roles of Cell Cycle Regulator CDCA5 in Human Solid Tumors.
He J; Zhou X; Wang X; Zhang Q; Zhang L; Wang T; Zhu W; Liu P; Zhu M
Int J Gen Med; 2022; 15():8257-8274. PubMed ID: 36438022
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive bioinformatics analysis reveals the oncogenic role of FoxM1 and its impact on prognosis, immune microenvironment, and drug sensitivity in osteosarcoma.
Shi S; Wang Q; Du X
J Appl Genet; 2023 Dec; 64(4):779-796. PubMed ID: 37782449
[TBL] [Abstract][Full Text] [Related]
4. Pan-cancer analysis identifies RNF43 as a prognostic, therapeutic and immunological biomarker.
Xu Y; Lin Z; Ji Y; Zhang C; Tang X; Li C; Liu T
Eur J Med Res; 2023 Oct; 28(1):438. PubMed ID: 37848933
[TBL] [Abstract][Full Text] [Related]
5. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
6. Clinical implication and immunological landscape analyses of ANLN in pan-cancer: A new target for cancer research.
Zhang L; Wei Y; He Y; Wang X; Huang Z; Sun L; Chen J; Zhu Q; Zhou X
Cancer Med; 2023 Feb; 12(4):4907-4920. PubMed ID: 36030492
[TBL] [Abstract][Full Text] [Related]
7. A pan-cancer analysis of the oncogenic role of ribonucleotide reductase subunit M2 in human tumors.
Li Y; Fu W; Geng Z; Song Y; Yang X; He T; Wu J; Wang B
PeerJ; 2022; 10():e14432. PubMed ID: 36518297
[TBL] [Abstract][Full Text] [Related]
8. Pan-Cancer Integrated Analysis Identification of SASH3, a Potential Biomarker That Inhibits Lung Adenocarcinoma Progression.
Chen X; Yuan Y; Ren W; Zhou F; Huang X; Pu J; Niu X; Jiang X
Front Oncol; 2022; 12():927988. PubMed ID: 35756681
[TBL] [Abstract][Full Text] [Related]
9. Invasive FoxM1 phosphorylated by PLK1 induces the polarization of tumor-associated macrophages to promote immune escape and metastasis, amplified by IFITM1.
Xu R; Lee YJ; Kim CH; Min GH; Kim YB; Park JW; Kim DH; Kim JH; Yim H
J Exp Clin Cancer Res; 2023 Nov; 42(1):302. PubMed ID: 37968723
[TBL] [Abstract][Full Text] [Related]
10. SAAL1, a novel oncogene, is associated with prognosis and immunotherapy in multiple types of cancer.
Yang W; Han B; Chen Y; Geng F
Aging (Albany NY); 2022 Aug; 14(15):6316-6337. PubMed ID: 35963646
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of FOXM1 in solid tumors: a systematic review and meta-analysis.
Li L; Wu D; Yu Q; Li L; Wu P
Oncotarget; 2017 May; 8(19):32298-32308. PubMed ID: 28427178
[TBL] [Abstract][Full Text] [Related]
12. H2A Histone Family Member Z (H2AFZ) Serves as a Prognostic Biomarker in Lung Adenocarcinoma: Bioinformatic Analysis and Experimental Validation.
Li Z; Hu M; Qiu J; Feng J; Zhang R; Wu H; Hu G; Ren J
Med Sci Monit; 2022 Jan; 28():e933447. PubMed ID: 35027526
[TBL] [Abstract][Full Text] [Related]
13. Identification of fatty acid metabolism-related molecular subtype biomarkers and their correlation with immune checkpoints in cutaneous melanoma.
Xu Y; Chen Y; Jiang W; Yin X; Chen D; Chi Y; Wang Y; Zhang J; Zhang Q; Han Y
Front Immunol; 2022; 13():967277. PubMed ID: 36466837
[TBL] [Abstract][Full Text] [Related]
14. A multidimensional pan-cancer analysis of DCAF13 and its protumorigenic effect in lung adenocarcinoma.
Wei S; Lu K; Xing J; Yu W
FASEB J; 2023 Apr; 37(4):e22849. PubMed ID: 36884358
[TBL] [Abstract][Full Text] [Related]
15. Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker.
Cheng X; Wang X; Nie K; Cheng L; Zhang Z; Hu Y; Peng W
Front Immunol; 2021; 12():646523. PubMed ID: 33679809
[TBL] [Abstract][Full Text] [Related]
16. CD1B is a Potential Prognostic Biomarker Associated with Tumor Mutation Burden and Promotes Antitumor Immunity in Lung Adenocarcinoma.
Li Z; Feng Y; Li P; Wang S; Liu X; Xia S
Int J Gen Med; 2022; 15():3809-3826. PubMed ID: 35418778
[TBL] [Abstract][Full Text] [Related]
17. A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma.
Huang S; Sun L; Hou P; Liu K; Wu J
Front Immunol; 2022; 13():944898. PubMed ID: 36148220
[TBL] [Abstract][Full Text] [Related]
18. An integrated model of CDCA5 and FOXM1 expression combined with a residual disease that predicts prognosis in ovarian cancer patients.
Zhang Q; Zhang R; Liu M; Wu H; Yang B
Cell Mol Biol (Noisy-le-grand); 2023 Oct; 69(10):143-149. PubMed ID: 37953569
[TBL] [Abstract][Full Text] [Related]
19. Expression of FSCN1 and FOXM1 are associated with poor prognosis of adrenocortical carcinoma patients.
Liang J; Liu Z; Wei X; Zhou L; Tang Y; Zhou C; Wu K; Zhang F; Zhang F; Lu Y; Zhu Y
BMC Cancer; 2019 Nov; 19(1):1165. PubMed ID: 31783819
[TBL] [Abstract][Full Text] [Related]
20. PRKCSH serves as a potential immunological and prognostic biomarker in pan-cancer.
Wang Q; Wang X; Li J; Yin T; Wang Y; Cheng L
Sci Rep; 2024 Jan; 14(1):1778. PubMed ID: 38245572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
